ArticleCureus2025
Rifampin Use in Staphylococcal Prosthetic Joint Infections.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Prosthetic joint infection (PJI) remains one of the most serious complications of prosthetic joint implantation. For patients with PJI managed with debridement, antibiotics, and implant retention (DAIR) surgical approach, two to six weeks of targeted intravenous antibiotics plus rifampin is typically recommended. Subsequently, rifampin plus a second oral antibiotic is given for a total of three versus six months for hip and knee arthroplasty infections, respectively. The goal of our study was to evaluate whether adjunctive rifampin affects treatment outcomes in patients with staphylococcal PJI. Methods We performed a retrospective study including patients aged > 18 with a diagnosis of prosthetic hip or knee infection due to staphylococcal species from January 2016 to December 2021. Patients were excluded if they did not receive appropriate anti-staphylococcal antibiotics, required resection arthroplasty or amputation, received a two-stage exchange as the initial surgical treatment, or were treated at another institution. The primary endpoint was treatment failure. Secondary endpoints included implant removal, long-term suppressive oral antibiotic utilization, hepatotoxicity, early rifampin discontinuation, and PJI-related mortality within one year. Results A total of 34 patients were included in the study, with 16 patients in the rifampin group (RIF) and 18 patients in the non-rifampin group (non-RIF). Most patients underwent DAIR for PJI management in both groups: 13/16 (81.3%) in RIF vs. 11/18 (61.1%) in non-RIF. The most common staphylococcalspecies causing infection was methicillin-susceptible
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.